Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.

MLA

Yuthavong, Yongyuth, et al. “Malarial Dihydrofolate Reductase as a Paradigm for Drug Development against a Resistance-Compromised Target.” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 42, Oct. 2012, pp. 16823–28. EBSCOhost, https://doi.org/10.1073/pnas.1204556109.

APA

Yuthavong, Y., Tarnchompoo, B., Vilaivan, T., Chitnumsub, P., Kamchonwongpaisan, S., Charman, S. A., McLennan, D. N., White, K. L., Vivas, L., Bongard, E., Thongphanchang, C., Taweechai, S., Vanichtanankul, J., Rattanajak, R., Arwon, U., Fantauzzi, P., Yuvaniyama, J., Charman, W. N., & Matthews, D. (2012). Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proceedings of the National Academy of Sciences of the United States of America, 109(42), 16823–16828. https://doi.org/10.1073/pnas.1204556109

Chicago

Yuthavong, Yongyuth, Bongkoch Tarnchompoo, Tirayut Vilaivan, Penchit Chitnumsub, Sumalee Kamchonwongpaisan, Susan A Charman, Danielle N McLennan, et al. 2012. “Malarial Dihydrofolate Reductase as a Paradigm for Drug Development against a Resistance-Compromised Target.” Proceedings of the National Academy of Sciences of the United States of America 109 (42): 16823–28. doi:10.1073/pnas.1204556109.